Takatori Eriko, Shoji Tadahiro, Miura Yuki, Takeuchi Satoshi, Yoshizaki Akira, Sugiyama Toru
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
J Obstet Gynaecol Res. 2013 Aug;39(8):1354-8. doi: 10.1111/jog.12062. Epub 2013 Jun 26.
There have been no case reports of the risk of serious adverse events associated with the administration of irinotecan hydrochloride (CPT-11) in patients with gynecologic cancer who are compound heterozygous for UGT1A16 and UGT1A128. A 71-year-old patient presented with recurrent stage IIIb cervical cancer. Combined chemotherapy was initiated with CPT-11 (60 mg/m² on days 1 and 8) plus nedaplatin (NDP; 80 mg/m² on day 1), with each cycle lasting for 28 days. The patient was a compound heterozygote for UGT1A16 and UGT1A128. Hematotoxic adverse events observed during the chemotherapy were grade 4 neutropenia, grade 3 anemia, and grade 4 thrombocytopenia, and the non-hematotoxic adverse events were grade 3 diarrhea and grade 3 fatigue. The findings in this patient indicate that CPT-11 should be administered with great care, even at a dose of 60 mg/m², in patients receiving combined therapy with CPT-11 and NDP who are compound heterozygous for UGT1A16 and UGT1A128.
对于携带UGT1A16和UGT1A128复合杂合子的妇科癌症患者，尚无关于盐酸伊立替康（CPT-11）给药相关严重不良事件风险的病例报告。一名71岁患者出现复发性IIIb期宫颈癌。开始联合化疗，使用CPT-11（第1天和第8天为60mg/m²）加奈达铂（NDP；第1天为80mg/m²），每个周期持续28天。该患者为UGT1A16和UGT1A128复合杂合子。化疗期间观察到的血液学不良事件为4级中性粒细胞减少、3级贫血和4级血小板减少，非血液学不良事件为3级腹泻和3级疲劳。该患者的研究结果表明，对于接受CPT-11和NDP联合治疗且为UGT1A16和UGT1A128复合杂合子的患者，即使剂量为60mg/m²，使用CPT-11时也应格外小心。
